Introduction to the Regeneron Class Action Lawsuit
- The Regeneron class action lawsuit seeks to represent purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).
- Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and certain of Regeneron’s top executives with violations of the Securities Exchange Act of 1934.
- If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit or just have general questions about you rights as a shareholder, please contact securities class action lawyer Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
- Lead plaintiff motions for the Regeneron class action lawsuit must be filed with the court no later than September 14, 2026.
Key Details of the Regeneron Class Action Lawsuit (2026)
Key Case Information in the Regeneron Class Action Lawsuit
- Class Period: Investors who purchased or acquired Regeneron securities between August 1, 2025, and May 15, 2026, are eligible to participate in the Regeneron class action lawsuit.
- Lead Plaintiff Deadline: If you suffered financial losses during this time, you have until September 14, 2026, to ask the court to appoint you as lead plaintiff.
- What’s Next: Being a “lead plaintiff” means you represent the broader class of investors, but anyone who bought stock during the class period may be eligible to recover damages if the class wins or settles. Investors who choose not to seek lead plaintiff status can still participate as an absent class member without filing extra paperwork.
What Regeneron Investors Can Do
How to Get Involved
- If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
- You may be notified of a class action by mail if you are an eligible class member.
- You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
- If you believe you may have a claim, you can contact a securities class action law firm for guidance.
What Is a Notice in a Class Action
- A notice in a class action refers to the formal communication sent to potential class members informing them about the lawsuit and their rights to participate in it.
- This notice is a crucial part of the class action process as it ensures that all individuals who may be affected by the outcome of the Regeneron class action lawsuit are aware of their rights and can choose whether to opt-in or opt-out of the class.
- The notice typically contains information about the nature of the Regeneron class action lawsuit, the claims being made, and the potential benefits or risks associated with participation. It also provides instructions on how to file a claim or request exclusion from the class.
- Overall, the notice serves to promote transparency and fairness in the class action process by ensuring that all affected individuals have an opportunity to exercise their legal rights.
Allegations in the Regeneron Class Action Lawsuit
Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.
The Regeneron class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Defendants created the false impression that they possessed reliable information demonstrating that Regeneron’s Phase III Fianlimab-Libtayo Study was well-poised for success, while minimizing risks to the study’s odds of achieving its primary endpoint and its overall statistical validity arising from the prolonged event rate slowdown;
- Regeneron’s preliminary statistical assumptions were fundamentally flawed;
- The active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and
- The trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, during Regeneron’s first quarter earnings call, defendants allegedly disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.”
On this news, the price of Regeneron stock declined more than 6%, according to the Regeneron class action lawsuit.
Then, after-market on May 15, 2026, Regeneron issued a press release allegedly announcing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).”
On this news, the price of Regeneron stock dropped nearly 10%, according to the Regeneron class action lawsuit.
Rights of Investors in the Regeneron Class Action Lawsuit
Investors affected by the Regeneron class action lawsuit possess specific rights that they can exercise. Understanding these rights is vital for anyone considering involvement in the Regeneron class action lawsuit.
Right to Information
- Investors have the right to receive accurate and timely updates regarding the Regeneron class action lawsuit.
- This includes information on the case’s progress, potential settlements, and any necessary actions they may need to undertake.
Right to Participate
- Affected investors have the right to join the Regeneron class action lawsuit.
- This allows them to collaborate with other investors in seeking compensation for their losses without the burden of filing individual lawsuits.
Right to Legal Representation
- Investors can seek legal counsel to navigate the complexities of the Regeneron class action lawsuit.
- Legal professionals can provide guidance and support throughout the process.
- If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
The Eligibility Criteria for Lead Plaintiff Appointment in the Regeneron Class Action Lawsuit
To be eligible for appointment as the lead plaintiff in the Regeneron class action lawsuit, an investor must meet the following criteria:
- Securities Acquisition: The Regeneron class action lawsuit seeks to represent purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).
- Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Regeneron and its executives.
- Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.
It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class Regeneron class action lawsuit as courts have consistently recognized the rights of non-U.S. investors in securities class actions.
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for an Regeneron class action lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of an Regeneron class action lawsuit and answer any questions you may have free of charge.
Contact Timothy L. Miles Today About a Regeneron Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the Regeneron class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube